Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NORETHIN 1 50M 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NORETHIN 1 50M 28.
LOESTRIN FE 1.5/30 vs NORETHIN 1/50M-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.
Norethindrone is a synthetic progestin that binds to the progesterone receptor, suppressing gonadotropin release and inhibiting ovulation. Estradiol provides negative feedback on the pituitary to reduce FSH and LH secretion, preventing follicular development.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.
One tablet orally once daily for 28 consecutive days per menstrual cycle. Each tablet contains 1 mg norethindrone and 50 mcg ethinyl estradiol.
None Documented
None Documented
Norethindrone: ~5-14 hours (terminal); Ethinyl estradiol: ~13-27 hours (terminal). Clinically, steady-state achieved within 5-7 days.
The terminal elimination half-life of norethindrone is approximately 7-8 hours following oral administration. Steady-state concentrations are achieved within 5-7 days. The half-life may be prolonged in patients with hepatic impairment.
Renal: ~50-60% (norethindrone metabolites); Fecal: ~20-30% (norethindrone); Ethinyl estradiol: primarily renal (~40-50%) and fecal (~20-50%) as glucuronide and sulfate conjugates.
Norethindrone (NET) and its metabolites are primarily excreted via the kidneys (50-70%) and feces (20-40%) as glucuronide and sulfate conjugates. Approximately 30-50% of an oral dose is recovered in urine within 24 hours, with extensive enterohepatic recirculation prolonging elimination.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive